Domestic Top Experts Join Regular Teams, Ushering in a New Era for Heavy-Ion Therapy Development
Professor Fan Ruitai, Standing Committee Member of the Chinese Medical Association Radiotherapy Oncology Committee and Former Chairman of Henan Provincial Medical Association Radiation Oncology Committee, Commences Regular Guidance Work at Lanzhou Heavy Ion Center
On July 29, Professor Fan Ruitai from the First Affiliated Hospital of Zhengzhou University, Henan Province, began a regular working arrangement at Gansu Wuwei Tumor Hospital’s Lanzhou Heavy Ion Center. His involvement injects a powerful new momentum into the development of the Center within the field of tumor treatment.
Professor Fan has achieved remarkable accomplishments in radiation oncology, boasting extensive clinical experience and profound academic expertise. His participation, alongside Professor Xu Bo and others, in regular heavy ion patient treatment enables the tailoring of scientific treatment plans for complex cases, propelling the hospital’s advancement in radiation oncology.
Gansu Wuwei Cancer Hospital is a state-owned public Grade A tertiary specialized oncology hospital. The Lanzhou Heavy Ion Center, operated by the hospital, is China’s second heavy-ion clinical application center with independent intellectual property. Collaborating with the nation's first heavy-ion therapy system, it began clinical operations on November 15, 2024. To date, the center has treated over 230 patients using photon and heavy-ion therapy for diseases including lung cancer, pancreatic cancer, liver cancer, and glioblastoma.
Aiming to establish a comprehensive, whole-life-cycle oncology treatment system, the hospital offers departments such as Radiation Therapy, Oncology/Hematology, Surgical Oncology, Integrated Traditional Chinese and Western Medicine Oncology Rehabilitation, Critical Care Medicine, Digestive Endoscopy Center, Imaging, Laboratory Medicine, Ultrasound Medicine, Blood Bank, and Hematology Center Laboratory. Services encompass photon radiotherapy, chemotherapy, heavy-ion therapy, medical and surgical comprehensive treatments, alongside imaging, medical laboratory, ultrasound, and bone marrow cytomorphology examinations.
Prof. Fan’s regular appointment aligns with the hospital’s long-standing talent development strategy. For years, the hospital has engaged renowned experts including Japan’s Prof.Tatsuaki Kanai (Gunma University) and Hirohiko Tsujii (formerly of NIRS), Germany’s Professor Jörg Hauffe (formerly of RPTC Munich Proton Center) and Prof. Olga, Taiwan’s Prof. Ren Yimin (formerly Chairman of Taiwan Radiation Oncology) and Prof. Wu Jiaming (Chang Gung Memorial Hospital), and the team of Prof. Wang Junjie (Chairman of the Chinese Medical Association Radiotherapy Oncology Branch). Recently, it further welcomed Japan’s Professor Yasuo Yoshioka (National Cancer Center Hospital East), Germany-Hungary’s Prof. György Kovács (Director of Lübeck Brachycenter, Italy), and Taiwan’s Prof. Wu Donghe (TMU Proton Center). This assembly of world-class experts forms an extensive intellectual network spanning the heavy-ion therapy chain and integrating Eastern and Western expertise, significantly strengthening the talent pool.
We firmly believe that under the exemplary leadership of Professor Fan and other leading experts, the Lanzhou Heavy Ion Center at Gansu Wuwei Cancer Hospital will harness innovation to accelerate toward becoming an internationally top-tier heavy-ion cancer treatment, research, and talent cultivation center. This will reshape the oncology treatment landscape, reigniting hope for global cancer patients and driving China’s oncology care to new heights of excellence.
Lanzhou Heavy Ion Center
Gansu Wuwei Tumor Hospital is a state-owned public Grade A tertiary specialized oncology hospital. The Lanzhou Heavy Ion Center, operated by this hospital, is China's second heavy-ion clinical application center with independent intellectual property rights. Together with the nation's first heavy-ion therapy system, its second domestically developed heavy-ion tumor treatment system commenced clinical operations at the Lanzhou Heavy Ion Center on November 15, 2024. As of now, the center has completed photon and heavy-ion treatments for over 230 patients, covering conditions such as lung cancer, pancreatic cancer, liver cancer, and glioblastoma 16.
The Lanzhou Heavy Ion Center has established an elite talent system, featuring expert workstations led by 50 top-tier authorities in the field. Key figures include:
● Professor Shen Wenjiang, Lifetime Honorary Professor of the Department of Radiation Oncology at Peking University Health Science Center;
● Professor Xu Bo, Standing Committee Member of the Radiotherapy Oncology Branch of the Chinese Medical Association;
● Professor Wang Junjie (Chairman of the Radiotherapy Oncology Branch of the Chinese Medical Association), who serves as the center's Dean, providing robust technical support for heavy-ion therapy .
Simultaneously, the center is equipped with cutting-edge medical devices, forming a solid foundation for precise and efficient heavy-ion treatments:
● Varian VitalBeam medical linear accelerator;
● Elekta Infinity 4D image-guided linear accelerator;
● 3.0T simulation MRI;
● GE Revolution 256-slice premium CT;
● Varian GammaMed Plus iX afterloader (Ir-192 source).
Aiming to build a comprehensive, whole-life-cycle oncology treatment system, the hospital has established multiple specialized departments, including:
● Radiation Therapy
● Medical Oncology/Hematology
● Surgical Oncology
● ntegrated Traditional Chinese and Western Medicine Oncology Rehabilitation
● Critical Care Medicine
● Digestive Endoscopy Center
● Imaging Department
Laboratory Medicine
● Ultrasound Medicine
● Blood Bank
● Hematology Center Laboratory
These departments deliver integrated treatments such as photon radiotherapy, chemotherapy, heavy-ion therapy, medical and surgical comprehensive care, alongside diagnostics including imaging, medical laboratory testing, ultrasound, and bone marrow cytomorphology examinations 167.